Skip to content

Neurofeedback in children with attention deficit hyperactivity disorder (ADHD)

Neurofeedback in children with attention deficit hyperactivity disorder (ADHD): a single-blind randomised controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN76187185
Enrollment
144
Registered
2009-02-05
Start date
2009-04-01
Completion date
Unknown
Last updated
2017-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention deficit hyperactivity disorder (ADHD) Mental and Behavioural Disorders Hyperkinetic disorders

Interventions

Participants will be randomly allocated to the following two groups (1:1 randomisation ratio): Intervention group: Neurofeedback of slow cortical potentials in addition to treatment as usual (TAU).

Sponsors

Ruhr-Universität Bochum (Germany)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Subjects meeting all of the following criteria will be considered for admission to the trial: 1. Both males and females, aged 7 to less than 10 years inclusive 2. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of ADHD, combined type 3. Ability of subject to understand character and individual consequences of clinical trial 4. Written informed consent must be available before enrolment in the trial 5. For women with childbearing potential, adequate contraception

Exclusion criteria

Exclusion criteria: 1. Below IQ 80 (Culture Fair Test [CFT]) 2. Bipolar disorder, psychosis, serious obsessive compulsive disorder (OCD), chronic serious tics or Tourette syndrome 3. Pharmacotherapy for severe anxiety and mood disorders and psychosis 4. Major neurological or medical illness 5. Non-German speaking child and primary caretaker 6. No telephone 7. Suicidal 8. Pregnancy and lactation 9. Participation in other clinical trials and observation period of competing trials, respectively

Design outcomes

Primary

MeasureTime frame
Change in ADHD Rating Scale at pre-test, treatment phase, post-test 1, post-test 2, follow-up.

Secondary

MeasureTime frame
The following will be assessed at pre-test, post-test 1, post-test 2, follow-up: 1. Clinical Global Impressions - Severity (CGI-S) Scale (at pre-test) and Clinical Global Impressions - Improvement (CGI-I) Scale (at post-test 1, post-test 2, follow-up) 2. Resumption of medication by choice of family during follow-up (yes/no) 3. Change in neuropsychological and neurophysiological parameters

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 19, 2026